Ipilimumab
FDA grants priority review, breakthrough therapy designation to Opdivo-Yervoy combination for HCC
10 important updates for Lung Cancer Awareness Month
Immunotherapy-chemotherapy combination extends OS in advanced NSCLC
Nivolumab-ipilimumab combination benefits women with advanced cervical cancer

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.
Immunotherapy combination improves OS compared with chemotherapy in lung cancer subset
BARCELONA, Spain — A combination of nivolumab and low-dose ipilimumab significantly improved OS compared with chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer, according to results of the randomized phase 3 CheckMate 227 study presented at European Society for Medical Oncology Congress.
Ipilimumab-nivolumab combination safe for historically unstudied patients with lung cancer
BARCELONA — The combination of low-dose, weight-based ipilimumab and flat-dose nivolumab demonstrated safety and efficacy as first-line treatment for patients with stage IV non-small cell lung cancer and comorbidities that traditionally preclude them from enrolling in clinical trials, according to results of the single-arm, nonrandomized CheckMate 817 study presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.